With a sample size of 6:
After 3 months, 3 out of 6 patients experienced a partial response, a 50% overall response rate(“ORR”) according to immune related response criteria (“irRC”);• The current disease control rate for this group is 66% (4/6);
Seems disappointing.
With a sample size of 18:
ORR of 33% (6/18) was reported according to the protocol when measured from start ofcombination treatment (cycle 5 of pembrolizumab treatment) in patients with suboptimal responseto pembrolizumab monotherapy;
Again, seems disappointing
Ann: Immutep presents new TACTI-mel data at ICI Europe Summit, page-3
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.020(7.02%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $1.171M | 3.900M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 101067 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8068 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
